Want to see ENTX full AI Analyst Report?
ENTX Stock Chart & Stats
$1.28
-$0.11(-4.20%)
At close: 4:00 PM EST
$1.28
-$0.11(-4.20%)
Day’s Range― - ―
52-Week Range$0.91 - $3.22
Previous CloseN/A
Volume29.71K
Average Volume (3M)123.78K
Market Cap
$96.61M
Enterprise Value$41.53
Total Cash (Recent Filing)$4.14M
Total Debt (Recent Filing)$448.00K
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Aug 07, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding49,290,234
10 Day Avg. Volume240,874
30 Day Avg. Volume123,776
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)6.84
Price to Sales (P/S)2133.59
P/FCF Ratio-11.98
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside603.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$54.58M
Bulls Say, Bears Say
Bulls Say
Oral Peptide Delivery & Phase 3 ProgressEntera's proprietary oral peptide delivery technology and advancement of EB613 into a Phase 3 pathway represent durable clinical development progress. Moving a single-tablet anabolic candidate toward Phase 3 reduces execution risk versus earlier stages, increases probability of later-stage partnership or commercialization, and reinforces the firm's core differentiated platform for converting injectables to oral therapies.
Low Leverage / Strong Balance Sheet PostureVery low debt (debt-to-equity ~0.04) gives Entera financial flexibility and lowers insolvency risk, providing runway to execute clinical programs or structure partnerships. This durable capital structure reduces interest burden and preserves strategic optionality for 2-6+ months, enabling prioritization of R&D rather than debt servicing.
Strategic Partnerships And Governance StrengtheningA 50/50 partnership with OPKO and recent board appointments strengthen technical, commercial and governance capabilities. Durable partnerships can share development costs and accelerate regulatory filings, while experienced directors improve oversight and credibility—supporting sustained pipeline execution and higher-quality strategic decisions over time.
Bears Say
Pre-revenue, Persistent Cash LossesEntera remains a pre-revenue biotech with recurring operating losses and no commercial cash inflows, a structural constraint on self-funding. Persistent negative earnings and no revenue base mean continued reliance on funding rounds or partnerships; this erodes equity over time and makes long-term program execution contingent on external capital.
Significant Authorized-share Increase / Dilution RiskA substantial rise in authorized shares and an expanded equity incentive plan materially increases potential dilution capacity. Structurally, this magnifies shareholder overhang and lowers per-share economic interest for existing holders if used for financing or compensation, affecting long-term equity value unless offset by strong clinical or commercial outcomes.
High Cash Burn; Limited RunwayTrailing cash burn is large relative to cash on hand; even after a private placement (cash ~$20.4M), management estimates runway only to Q1 2027. This creates a persistent funding need and execution risk: further capital raises could be dilutive or conditional, and constrained liquidity may force prioritization or delay of programs.
Entera Bio News
ENTX FAQ
What was Entera Bio Ltd’s price range in the past 12 months?
Entera Bio Ltd lowest stock price was $0.91 and its highest was $3.22 in the past 12 months.
What is Entera Bio Ltd’s market cap?
Entera Bio Ltd’s market cap is $96.61M.
When is Entera Bio Ltd’s upcoming earnings report date?
Entera Bio Ltd’s upcoming earnings report date is Aug 07, 2026 which is in 15 days.
How were Entera Bio Ltd’s earnings last quarter?
Entera Bio Ltd released its earnings results on May 08, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.08 by $0.01.
Is Entera Bio Ltd overvalued?
According to Wall Street analysts Entera Bio Ltd’s price is currently Undervalued.
Does Entera Bio Ltd pay dividends?
Entera Bio Ltd does not currently pay dividends.
What is Entera Bio Ltd’s EPS estimate?
Entera Bio Ltd’s EPS estimate is -0.08.
How many shares outstanding does Entera Bio Ltd have?
Entera Bio Ltd has 49,290,234 shares outstanding.
What happened to Entera Bio Ltd’s price movement after its last earnings report?
Entera Bio Ltd reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.08. Following the earnings report the stock price went down -10%.
Which hedge fund is a major shareholder of Entera Bio Ltd?
Currently, no hedge funds are holding shares in ENTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Entera Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (603.13% Upside)
$9.00 (603.13% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 8.3%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.41%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-39.22%
Trailing 12-Months
Company Description
Entera Bio Ltd
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
ENTX Stock 12 Month Forecast
Average Price Target
$9.00
▲(603.13% Upside)
Technical Analysis
Ownership Overview
4.32% Insiders
0.04% Mutual Funds
13.13% Other Institutional Investors
82.50% Public Companies and
Individual Investors